Arzneimittel mit dem Wirkstoff Follitropin alfa (ATC: G03GA05)
Germany · Magdeburg · how to bid here →
Your path to submission
- Deadline: 31 August at 00:00 — 722 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 4 months (36 awards, most recently September 2026) — the next award is due around January 2027 by that rhythm. The last award went to Swedish Orphan Biovitrum GmbH.n = 36
- 43% of this buyer's awards went to companies that had already won here before (108 awards since 2018, spread over 51 companies). That is well below the sector norm (62%) — this buyer switches suppliers more often than others.n = 108 awards since 2018
- The median procedure drew just one bid (71 procedures with a bid count); 63% ended with a single bidder. Sector: median 2 bids.n = 71
- The award came in at a median 100% of the estimated value (5 awards with both estimate and value) — pricing at the estimate is usually about right here. Sector: 100%.n = 5
- Across 181 procedures with structured selection criteria, this buyer most often required: Trade register enrolment (181 of 181).n = 181
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 07/09/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 252 contracts went to foreign companies over the last 3 years (of 21,727 recorded awards) — mostly from Austria, Netherlands, France.
Typical field: median 4 (from 82 awards).
What the buyer is looking for
Gegenstand dieser Veröffentlichung ist der Abschluss von nicht exklusiven Rabattverträgen gemäß § 130a Abs. 8 SGB V zu Fertigarzneimitteln mit dem Wirkstoff Follitropin alfa (ATC: G03GA05) im Rahmen eines sogenannten "open-house-Modells". Unter Vorgabe einheitlicher Vertragskonditionen sowie eines einheitlichen Zugangsverfahrens wird allen geeigneten und interessierten pharmazeutischen Unternehmen oder Gemeinschaften pharmazeutischer Unternehmen der Abschluss bzw. Beitritt zu einem Rabattvertrag nach § 130a Abs. 8 SGB V zu den vorgenannten Wirkstoffen bzw. Arzneimitteln angeboten. Interessierte pharmazeutische Unternehmen können dazu bei der genannten Kontaktadresse die Teilnahmeunterlagen sowie den jeweiligen Vertrag anfordern. Voraussetzung für den Abschluss eines Vertrages ist, dass das interessierte pharmazeutische Unternehmen die angeforderten Teilnahmeunterlagen vollständig ausgefüllt und unterzeichnet.
What you must prove — eligibility criteria
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| PIK AG | 5 | 2025 |
| GlaxoSmithKline GmbH & Co. KG · München | 5 | 2012–2026 |
| Novartis Pharma GmbH · Nürnberg | 5 | 2013–2026 |
| Städtische Werke Magdeburg GmbH & Co. KG | 4 | 2025 |
| RpDoc Solutions GmbH · Saarbrücken | 4 | 2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.